Qsemble Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Qsemble Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,088	Closed	-$3.39M	–	454
2025 Q4	$3.39M	Buy	+57,088	New	+$3.11M	0.28%	123
2025 Q3	–	Sell	-21,827	Closed	-$1.2M	–	469
2025 Q2	$1.2M	Sell	21,827 -21,438	-50%	-$1.26M	0.12%	224
2025 Q1	$3.06M	Buy	43,265 +10,929	+34%	+$735K	0.32%	114
2024 Q4	$2.13M	Buy	+32,336	New	+$2.17M	0.28%	128
2024 Q2	–	Sell	-8,848	Closed	-$773K	–	435
2024 Q1	$773K	Sell	8,848 -960	-10%	-$85.9K	0.17%	205
2023 Q4	$946K	Sell	9,808 -8,592	-47%	-$760K	0.24%	160
2023 Q3	$1.63M	Buy	18,400 +7,100	+63%	+$632K	0.3%	117
2023 Q2	$979K	Buy	+11,300	New	+$1.06M	0.7%	56
2023 Q1	–	Sell	-8,100	Closed	-$838K	–	246
2022 Q4	$838K	Buy	+8,100	New	+$760K	0.58%	60

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qsemble Capital Management's BMRN Position: Q1 2026 in Review

Qsemble Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 57,088 shares — an estimated $3.39M sold.

Qsemble Capital Management first reported a position in BMRN in Q4 2022 and held it in 9 quarters. The position peaked at $3.39M in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Qsemble Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Qsemble Capital Management sold 57,088 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $3.39M.
Qsemble Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 9 quarters.
Qsemble Capital Management's BioMarin Pharmaceuticals position peaked at $3.39M in Q4 2025.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.